 CNS Pharmaceuticals, Inc., Nasdaq: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that since the May 1st, 2020 temporary suspension by the Securities and Exchange Commission SEC in the trading of CNS Pharmaceuticals, Inc. CNSP securities, additional information has come to the Companys attention regarding information disseminated by third parties. 